Preceptis Medical manufactures pediatric surgical technologies designed especially for the unique needs of children and the medical professionals that care for them. The Hummingbird® TTS (Tympanostomy Tube System) minimizes surgical trauma (pain) during ear tube placement allowing physicians the option to use moderate sedation for routine ear tube procedures.
This important alternative provides an option for less anesthesia in young children, potentially reduces healthcare costs by moving the procedure out of the O.R. – and allows added convenience for families and their children who undergo over 1.2 million ear tube procedures in the U.S., annually.1
Steve Anderson is the CEO of Preceptis Medical, Inc. Prior to this position, he was the President of Acorn Cardiovascular, Inc., a medical device manufacturer developing life-sustaining therapies for the treatment of systolic heart failure. Steve has 30 years of experience in the medical device industry, starting with Medtronic and including senior management positions at St. Jude Medical, TÜV Product Service, St. Croix Medical, and Acorn Cardiovascular. His specific core competencies include development, regulatory, clinical, reimbursement, quality, and compliance.
Steve has a BS in Materials Engineering and an MS in Biomedical Engineering from the University of Minnesota. He was an Adjunct Professor at the University of St. Thomas Graduate School, has served on multiple boards for medical device companies (both public and private), and has authored numerous publications on medical device regulation and reimbursement (both US and worldwide).
Currently John is EVP at Cedar Point Capital that focuses on capital formation for private companies, primarily in healthcare. He also serves on the boards of Medicom Health Interactive, Admedus Ltd and Phraxis Inc.
Previously John was Co-Founder, Chairman and CEO of NeoChord Inc, Prior to NeoChord, John spent ten years at Guidant Corp where he was VP of Sales in the Cardiac Surgery and Cardiac Rhythm Management divisions. In 1991, John co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices. John received a B.A. in Speech Communications from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota.
Buzz has been an active investor and advisor in the medical technology industry for over 30 years. Buzz is a founding member of SightLine Partners and led the effort to establish it as an independent firm in 2004 by acquiring the healthcare venture capital operations from Piper Jaffray Companies. Prior to SightLine, Buzz established Piper Jaffray’s dedicated venture investing in 1992, serving as President and Managing Director of Piper Jaffray Ventures from 1992-2004. From 1986 to 1992 he co-headed Piper Jaffray’s healthcare-focused Investment Banking activities. In addition to over 25 years of venture capital experience, Buzz has been actively involved in a broad range of transactions for healthcare companies including mergers and acquisitions, corporate partner agreements, public offerings and private placements of equity and debt.
Michael K. Loushin, MD
Founder and Board Member
Dr. Loushin is a board certified anesthesiologist with over 14 years of clinical experience and expertise in medical device and IP development, clinical studies, and perioperative medicine. Dr. Loushin is a partner with Twin Cities Anesthesia Associates, PA and an adjunct in the Department of Anesthesiology, University of Minnesota. Dr. Loushin completed anesthesiology residency at the University of Minnesota, and his clinical practice includes pediatric, cardiac, and general anesthesia. Dr. Loushin has served as medical director of perioperative services at University of Minnesota Medical Center-Fairview and Fairview Maple Grove Surgery Center providing leadership in patient safety, OR efficiency, and LEAN/process improvement.
David S. Overman
Chief Operating Officer for Prime Therapeutics
David S. Overman, was appointed May of 2017, interim Chief Operating Officer for Prime Therapeutics, a pharmacy benefit manager (PBM) serving nearly 26 million people. Prior to this, he served as President and Chief Operating Officer for Children’ Hospital and Clinics of Minnesota for the past 11 years. Responsible for the performance of the Children’s health system, implementing strategic initiatives, delivering cost effective, quality care with exceptional patient family experience. Prior to joining Children’s, Mr. Overman served as vice president of information systems at Express Scripts, a large national company that manages pharmacy benefits. During his 9 years at Express Scripts, he led an information technology staff of more than 800 employees.
Mr. Overman has a Bachelor of Arts Degree in Business administration from Lakeland University and serves on the board of directors for Ronald McDonald House Charities, Preceptis Medical Inc. and Lake Wapogasset Lutheran Bible Camp.
Mr. Geyen brings a 25-years of leadership experience in fast-paced, rapidly growing public and private life science companies. Most recently he served as Chief Financial Officer of NeuWave Medical through the acquisition by Johnson & Johnson. Prior to NeuWave Medical, he served as the Chief Financial Officer of Celleration, a venture-backed company focused on developing and commercializing therapeutic ultrasound healing technologies, through their acquisition by Alliqua BioMedical. Previously, he served as the Chief Financial Officer of Restore Medical, a manufacturer of innovative medical devices to treat sleep-disordered breathing, where he successful completed an initial public offering and the eventual sale of Restore to Medtronic. Mr. Geyen also previously served as Chief Financial Officer of Acorn Medical and Urologix and began his career at Ernst and Young. Mr. Geyen holds a Bachelor’s degree in Business Administration and Accounting from the University of St. Thomas – St. Paul, MN. Mr. Geyen is also a licensed CPA (Inactive).
- Range derived from the following sources: American Academy of Otolaryngology (AAO) 2013 1.3M – largest industry association; Thomson Reuters from 2013 of 1.23M plus 200K in adults; Millennium Research Group 2013 1.4M (MRG data for private payers: hospitals and ASCs)